Cancer Immunol Immunother
-
Publication Venue For
- PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.. 70:1049-1062. 2021
- Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival. 2021
- Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection.. 70:475-483. 2021
- Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients.. 69:1375-1387. 2020
- An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.. 66:1529-1544. 2017
- Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.. 65:1533-1544. 2016
- A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.. 65:383-392. 2016
- Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery.. 65:171-180. 2016
- Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.. 65:205-211. 2016
- Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.. 64:977-987. 2015
- CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.. 64:677-688. 2015
- Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.. 64:585-598. 2015
- Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.. 64:419-427. 2015
- A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.. 62:1649-1662. 2013
- Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.. 62:1293-1301. 2013
- Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models.. 62:1011-1019. 2013
- BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.. 62:983-987. 2013
- Elevated level of peripheral CD8(+)CD28(-) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy.. 62:1123-1130. 2013
- Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.. 61:1941-1951. 2012
- Modeling flow cytometry data for cancer vaccine immune monitoring.. 59:1435-1441. 2010
- Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.. 59:1131-1135. 2010
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.. 59:663-674. 2010
- Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.. 59:609-618. 2010